

### COMPANY OVERVIEW

Caladrius is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34+ cell therapy platform: CLBS12, recipient of a SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; CLBS14-CMD, subject of the proof-of-concept ESCaPE-CMD clinical study in the U.S. for the treatment of coronary microvascular dysfunction; and CLBS14-NORDA, recipient of a RMAT designation in the U.S. and for which we are in preparations to commence a Phase 3 clinical trial in no option refractory disabling angina.

### C-SUITE LEADERSHIP TEAM

**David Mazzo, PhD**

*President  
Chief Executive Officer*

**Douglas Losordo, MD**

*Executive Vice President  
Global Head of R&D  
Chief Medical Officer*

**Joseph Talamo, CPA, MBA**

*Senior Vice President  
Chief Financial Officer*

### INVESTMENT HIGHLIGHTS

#### **Late-stage therapeutics development company**

- Pioneering advancements of cell therapies in cardiovascular disease
- Three principal development programs; 2 designated “breakthrough”\*
  - CD34+ cells for ischemic repair (CLBS12\*, CLBS14-CMD, CLBS14-NORDA\*)

#### **CD34+ cell therapy technology platform includes nearer-term commercial opportunities**

- CLBS12 is an ongoing critical limb ischemia study in Japan with SAKIGAKE designation for expedited review and eligible for early conditional approval
- CLBS14-CMD is an ongoing proof-of-concept Phase 2 study in the USA for coronary microvascular dysfunction and is supported by a grant from the NIH
- CLBS14-NORDA is in Phase 3 development in the USA for no option refractory disabling angina

#### **Financially stable and debt-free**

- Strong balance sheet (~\$38 million cash as of March 31, 2019)
- Low operating cash burn (cash projected through 2Q 2020)


#### **Dedicated and highly motivated leadership team with extensive experience in biopharmaceutical development**

### MARKET SNAPSHOT

### POTENTIAL VALUE CREATING MILESTONES

Ticker Symbol	CLBS		<b>2Q 2019</b>	Finalize CLBS14-NORDA clinical plan with FDA
Exchange	NASDAQ		<b>2Q 2019</b>	Complete enrollment in ESCaPE-CMD Phase 2 study
52-Week Price Range	\$2.77 - \$11.65		<b>2H 2019</b>	Announce ESCaPE-CMD Phase 2 study topline data
Shares Outstanding (3/31/19)	~10.4 mil		<b>2H 2019</b>	Complete enrollment in CLBS12 Phase 2 study
Cash & Investments (3/31/19)	~\$38 mil		<b>2H 2019</b>	Initiate CLBS14-NORDA pivotal Phase 3 study
Fiscal Year-End	December 31		<b>1H 2020</b>	Announce CLBS12 Phase 2 study topline data


# ROBUST PRODUCT PIPELINE




## CD34+ CELL THERAPY PLATFORM

- CD34 is a cell surface protein that identifies a subset of mononuclear cells in the bone marrow and circulation
- CD34+ cells are pre-programmed vascular repair cells that promote angiogenesis of the microvasculature. Caladrius' proprietary platform technology selects and delivers a potent, concentrated population of the patient's own CD34+ cells for optimal therapeutic benefit

### Simple, rapid, scalable and economical autologous cell therapy process



- G-CSF mobilization eliminates need for surgical bone marrow aspiration
- Four days or less from donation to treatment
- Well characterized, reliable GMP process - easily scaled to meet increasing demand




- More than 700 subjects studied in randomized double-blind placebo-controlled trials provide consistent evidence of therapeutic benefit and tolerance

- Improved mortality, reduced chest pain and increased exercise tolerance in refractory angina<sup>1</sup>
- Reduced amputation in critical limb ischemia<sup>2</sup>
- Improved function in claudication<sup>3</sup>

<sup>1</sup>Losordo et al. *Circ Res* 2011.; Poyscic et al. *JACC Cardiovasc Interv.* 2016.  
<sup>2</sup>Losordo et al. *Circ Cardiovasc Interv* 2012.  
<sup>3</sup>From US study (n=17); Not yet published

## T REGULATORY CELL THERAPY PLATFORM

- Caladrius' T regulatory cell technology is based on autologous *ex vivo* expanded polyclonal T regulatory cells, which are functionally enhanced prior to re-introduction to the patient
- Therapeutic T regulatory cells (Tregs) are thought to be active in the treatment of autoimmune diseases in which deficient Treg activity results in the patient's immune system attacking the body's own beneficial tissues
- Caladrius' technology to enhance autologous Treg number and function leverages the native immune regulatory mechanisms, offering a path to true disease modification



- The potential of Tregs as a therapeutic platform differentiates itself from available therapeutics and almost all other investigational agents in development through:

- Disease modification via restoration of immune tolerance as the most proximal/root cause of the autoimmune disease pathways, in contrast to targeting less pivotal and redundant downstream effects
- Freedom from indiscriminate immune suppression of vital effector functions of the immune system
- Specific homing to disease affected organs, thus targeting tolerance to where it is needed most

CALADRIUS BIOSCIENCES, INC.  
[www.caladrius.com](http://www.caladrius.com)

CORPORATE HEADQUARTERS  
 110 Allen Road, 2nd Floor  
 Basking Ridge, NJ 07920  
 Tel: 908.842.0100

INVESTOR RELATIONS CONTACT  
 John D. Menditto  
 Tel: 908.842.0084  
 E-mail: [jmenditto@caladrius.com](mailto:jmenditto@caladrius.com)